Our Origin Story.

Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.

The ICER Impact.

New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million

Read More

Engaged with over 400 patient groups and patient reps

The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.

 

Current

Policy Papers.

Easy access to our latest policy papers

Special Report on COPD Therapies as Part of CMS Public Comment Process on Medicare Drug Price Negotiations

ICER developed a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report was submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.

Read More

Examining Strategies to Ensure Affordable Access for Obesity Medications

ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.

The paper seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.

Read More

Unsupported Price Increases

Of 10 high-expenditure drugs that had substantial 2023 net price increases, five were not supported by new clinical evidence; these increases accounted for $815 million in additional costs in 2023.The five drugs with unsupported price increases are Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz.

Read More

Cost-Effectiveness, the evLYG,

the QALY, and Fair Drug Pricing.

Learn More.